Life sciences partner Katherine Wang (Shanghai) was quoted extensively in an article titled “Medtech and pharma: heed stricter China clinical trial rules for hospitals” appearing in Scrip Regulatory Affairs on Oct. 31, 2014. In the article, Ms. Wang discusses the new NHPFC rules for medical institutions conducting clinical trials in China that became effective in October and suggests that medical device and drug companies should review their internal policies in light of the new measures.
To read the article, click here.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.